- 1
- 2
H4D
Dermatology
Infectious Diseases - Vaccines
Nutrition and Weight Loss
Ophthalmology
Otolaryngology (Ear, Nose, Throat)
Pulmonary/Respiratory Diseases
Psychiatry/Psychology
Your innovative solution
The Consult Station
Access to care is an increasing challenge throughout the world at a time when chronic diseases, an ageing population and increasing costs challenge current medical organizations. H4D
Corporations, hospitals, retirement communities, rural and remote areas.
1) Quality and certification for professional medical use, 2) Large functional coverage for primary care uses, 3) Convenient and easy access to a physician, 4) Cost savings.
VINCENT HILLENMEYER
COOHackensack UMC Mountainside Hospital
HackensackUMC Mountainside is unique among New Jersey hospitals. While many others are seeking new owners because their futures remain uncertain, one of the nation’s most prestigious hospitals, HackensackUMC and LHP Hospital Group, Inc. one of the nation’s most innovative capital and healthcare management firms are choosing to affiliate with HackensackUMC Mountainside because of its strength and stability.
Mr Joseph Patanella
Assistant Chief Operating OfficerHarkerBIO
HarkerBIO possesses unique capabilities that accelerate the development of new drugs.
HarkerBIO is located on the growing Buffalo Niagara Medical Campus, a consortium of the region's premier health care, life sciences research, and medical education institutions, all located on 120 acres in downtown Buffalo, New York.
biomolecular crystallization
Mr Artem Evdokimov
Chief Scientific OfficerHARMONIC PHARMA
THE COMPANY
Finding new uses of safe drugs based on polypharmacology profiling: Armonco® a clinical candidate for lung cancer.
OBJECTIVES FOR THIS EVENT
Harmonic Pharma is looking for a company which would be interested in acquiring the exclusive license of Armonco® in order to perform its clinical development in lung cancer.
TECHNOLOGY AND PRODUCTS
Harmonic Pharma has developed a unique and innovative know-how combining polypharmacology with relevant animal models mimicking human diseases. This expertise has been applied to identify a clinical candidate for lung cancer from existing safe drugs: Armonco® has been developed to be licensed out for a clinical trial.
KEY ADVANTAGES
New targeted therapy for lung cancer
Armonco® acting in monotherapy and in combination with existing treatments including inhibitor antibodies
Clinical candidate with already well documented safety in man
Cost-effective process and shortening time to market
Consolidated IP including a specific formulation
Ø Seeking companies interested in discussing common business opportunities in the cancer area
Arnaud Sinan KARABOGA
CSOHEALTHePRACTICES
HEALTHePRACTICES (HeP) provides expertise in assisting healthcare practices and technology companies to achieve specific goals toward the delivery of excellent care to their clients. We provide Business Development and Consulting support with a focus on all aspects of telemedicine with a particular interest in medical imaging.
Healthios
HealthiosXchange is the premier online capital market dedicated exclusively to the global healthcare industry. Employing “Crowdfunding” as the cornerstone of a new paradigm in healthcare investing, the H/X offers direct access from "seed" to "exit" to the most promising healthcare companies on a “No Fee No Carry” basis.
Healthios, the founder of HealthiosXchange, is a boutique investment bank dedicated exclusively to the global healthcare industry:
- The most compelling growth companies
- The most dynamic industry sectors
- The most sophisticated institutional investors
- The most active strategic buyers and partners
Healthios seeks to be the premier investment bank serving the global healthcare industry by combining the experience of (52) transactions in 17 countries with unique access to capital, resources and ideas that are the foundation of superior value.
Financing, Partnering, Capital Markets, M&A
Ms Jessica Liang
AnalystHemarina SA
CNS-Neurology
Dental and Oral Health
Dermatology
Gastroenterology / Hepatology
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Pulmonary/Respiratory Diseases
Rare Disease
Your innovative solution
Hemarina develops products that constitute a decisive technological breakthrough in regard to current or past developments of hemoglobin-based oxygen carriers (HBOCs).
HEMOXYcarrier� = Universal oxygen carrier (Lack of blood worldwide is ~ 100 millions liters per year) - HEMO2Life : Organ & Tissue preservation - HEMHealing : Wound Healing & Repair
1/ Blood Oxygen Transporter, 2/ Organ & Tissue preservation, 3/ /Wound Healing & Repair
1/ Unique know how from development to production of oxygen carriers 2/ Strong academic network & partnerships 3/ Broad intellectual property covering Hemarina's technology 4/ international publications
Franck Zal
CEOHenry Schein
Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and NASDAQ 100® Indexes, Henry Schein employs more than 18,000 Team Schein Members and serves more than one million customers.
The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 100,000 branded products and Henry Schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.
Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 30 countries. The Company's sales reached a record $10.4 billion in 2014, and have grown at a compound annual rate of approximately 16 percent since Henry Schein became a public company in 1995.
For more information, visit the Henry Schein website at www.henryschein.com